secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0000950170-24-095414
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen Q2 net loss widens to $25.3M on $20.4M warrant loss; cash at $37.8M
----------------------------------------------------------------------------

- Cash and cash equivalents $37.8M as of June 30, 2024, up from $27.3M at March 31, 2024.
- Net loss $25.3M vs $9.4M in Q2 2023; includes $20.4M loss on issuance of pre-funded warrants and warrants.
- R&D expenses decreased to $5.3M from $6.9M YoY, reflecting 2023 restructuring.
- Phase 1b trial of SZN-043 for severe alcoholic hepatitis ongoing; proof-of-concept data expected H1 2025.
- Boehringer Ingelheim partnership for SZN-413 may trigger $10M milestone if lead candidate nominated in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000095017024095414/0000950170-24-095414-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000095017024095414/srzn-20240812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-095414

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer